Welcome to our dedicated page for Senti Bioscience SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company and emerging growth company, Senti Bio uses these filings to report on its financial condition, corporate governance matters, and progress across its cell and gene therapy programs built on its Gene Circuit platform.
Current and periodic reports such as Forms 10-Q and 10-K (when available) typically include detailed discussions of research and development activities, risks related to clinical-stage operations, and updates on key programs like SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy product candidate for CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS. These reports also describe the company’s status as an emerging growth company and provide information on cash, operating expenses, and accumulated deficit.
Form 8-K filings capture material events, including quarterly financial result announcements and outcomes of the annual meeting of stockholders. For example, recent 8-Ks reference press releases on financial results and describe voting results for director elections and auditor ratification. Investors use these documents to track significant corporate developments beyond scheduled periodic reports.
Through this page, users can also review proxy statements and related governance materials, which explain matters submitted to stockholders, such as board composition and auditor selection. Insider transaction reports on Form 4, when present, provide visibility into equity transactions by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify disclosures on clinical programs, Gene Circuit platform risks, and financial trends. Real-time updates from EDGAR ensure that new SNTI filings, from 10-K and 10-Q reports to 8-K current reports and Forms 3 and 4, are surfaced as they become available.
Senti Biosciences officer reports tax share withholding from RSU settlement. On 02/02/2026, Pres. & Chief Med. & Dev. Officer Kanya Rajangam had 1,384 shares of Senti Biosciences common stock withheld at a price of $0 per share to cover income tax obligations on vested restricted stock units.
These shares were withheld by the company and the transaction did not involve an open market sale. Following this tax-related withholding, Rajangam directly beneficially owns 85,600 shares of Senti Biosciences common stock.
Senti Biosciences CEO Timothy K. Lu reported a routine tax-related share withholding. On February 2, 2026, the company withheld 4,191 shares of common stock to cover income tax obligations tied to vested restricted stock units, which was not an open market sale.
After this withholding, Lu directly beneficially owned 720,249 shares of common stock. The filing also lists 52,839 shares held indirectly by his spouse and another 52,839 shares held by Luminen Services, LLC as trustee of the Luminen Trust, for which Lu disclaims beneficial ownership except for any pecuniary interest.
Celadon Partners SPV 24 and Celadon Partners, LLC report a 45% beneficial stake in Senti Biosciences, Inc. common stock, including warrant shares subject to a 45% cap. They report beneficial ownership of 13,511,322 shares, which includes 3,734,322 shares issuable upon exercise of warrants, calculated against 26,290,838 shares outstanding as of October 31, 2025.
The investors state they are in preliminary discussions with Senti about a potential financing of at least $10.0 million through convertible bonds issued by a new Senti subsidiary. These bonds would be convertible into equity of the subsidiary or exchangeable for Senti common stock, with proceeds intended to advance CMC and clinical trials for v2.0 process development and GMP manufacturing. They are also exploring possible restructuring or merger and acquisition transactions with Senti that could involve changes to the company’s capital structure. The investors report no Senti stock transactions in the past 60 days.
Senti Biosciences (SNTI) filed its Q3 2025 10‑Q, reporting a net loss of $18.1 million for the quarter and $47.0 million for the nine months. Cash and cash equivalents were $12.2 million at September 30, 2025, down from $48.3 million at year‑end, and management concluded that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
Operating expenses were $16.9 million in Q3, driven by R&D $10.5 million and G&A $6.4 million. Net cash used in operating activities was $36.6 million for the nine months. The company also recorded a $3.3 million reversal of previously recognized sublease income tied to related‑party GeneFab after determining collectibility was not probable. As of quarter‑end, GeneFab owed $4.7 million in past‑due sublease rent; $1.0 million was received in October.
Senti received a default notice on its Alameda lease for ~$0.4 million of unpaid rent; discussions to cure are ongoing and the lease remains in place. The company converted 21,157 shares of Series A preferred into 21,157,000 common shares in March 2025. Shares outstanding were 26,290,838 as of October 31, 2025. CIRM grant receipts totaled $7.4 million to date, supporting the SENTI‑202 program.
Senti Biosciences (SNTI) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company reported this via an Item 2.02 Form 8-K dated November 13, 2025, with the press release attached as Exhibit 99.1.
Consistent with General Instruction B.2., the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into Securities Act filings.
Celadon Partners disclosed a 45.0% beneficial ownership stake in Senti Biosciences, Inc. (SNTI), reporting ownership of 13,404,441 shares, which includes 3,627,441 shares issuable upon exercise of warrants subject to a 45% ownership cap. The percentage is calculated using 26,160,206 shares outstanding as of July 31, 2025. The filing (Amendment No. 2 to Schedule 13D) states Celadon intends to continue preliminary discussions with Senti about a potential financing and may seek changes to capital structure and Board composition, including potential additional Board representation. Celadon also reserves the right to buy or sell securities or pursue hedging or other actions as circumstances evolve.